Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, offers advice to health systems on how they can incorporate some of Emory Healthcare's strategies to promote biosimilar uptake.
Transcript
What strategies can health care institutions like Emory Healthcare implement to improve biosimilar adoption rates?
Haumschild: There are so many strategies, and it really depends on what's going on with your individual institution. I think a few of them are doing a baseline survey. You need to recognize where your barriers are because there are so many, but every institution is different. And so do we recognize is it related to the electronic medical record? Is it related to provider understanding and uptake? What about your finance team? Do they recognize that lower expense might recognize lower revenue, but that might not necessarily be a bad thing all the time?
I think when you can work through those barriers and designate key stakeholders to make more expedited decisions, that allows for faster uptake. Also, if you can get a P&T [pharmacy and therapeutics] policy approved, where pharmacy might have the ability to interchange biosimilars based on payer or individual hospital preferences, it allows for more timely adjudication and delivery of care to the patient and doing it at a reduced cost. So, I think if you can work through those barriers, focus on the electronic medical record, your key stakeholders clinically and financially, and create some of these tools, that's going to create better uptake, faster uptake, and you're going to be more efficient with your care model.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.